Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
READY-BREATHE phase 2b trial of JNJ-95597528 in inadequately controlled moderate to severe asthma
jRCT2031260450Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-95597528 in asthma (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of asthma exacerbations through Week 48. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
JNJ-95597528
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031260450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260450.